Pituitary production of prolactin and prolactin-suppressing drugs

Lupus

Volumn 10, Issue 10, 2001, Pages 660-664

  Tansey, M J ^a   Schlechte, J A ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Bromocriptine; Cabergoline; Pituitary tumor; Prolactin; Prolactinoma

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN;

AMENORRHEA; CLINICAL FEATURE; DOPAMINERGIC SYSTEM; FEMALE; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS; HYPOPHYSIS TUMOR; INFERTILITY; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROLACTIN SYNTHESIS; PROLACTINOMA; REGULATORY MECHANISM; REVIEW; TUMOR VOLUME;

DOPAMINE AGONISTS; HUMANS; HYPERPROLACTINEMIA; HYPOTHYROIDISM; PITUITARY GLAND; PROLACTIN; PROLACTINOMA; STRESS;

EID: 0034753972     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120301717164886     Document Type: Review

References (42)

1. Dopamine D2 receptor mediates both inhibitory and stimulatory actions on prolactin release
2. Dopamine receptors on intact anterior pituitary cells in culture: Functional association with the inhibition of prolactin and thyrotropin
3. Interactions of dopamine and thyrotropinreleasing hormone in the regulation of prolactin release in lactating rats
4. Effects of dopamine infusion of pituitary hormone secretion in humans
5. A prolactin-inhibiting factor within the precursor for human gonadotropin-releasing hormone
6. Prolactin
7. Prolactin and thyrotropin release in man by synthetic pyroglutamyl-histidyl-prolinamide
8. Human prolactin: 24-Hour pattern with increased release during sleep
9. In vivo effects of estrogen on ovine pituitaries: Prolactin and growth hormone biosynthesis and messenger ribonucleic acid translation
10. Pattern of increase in circulating prolactin levels during human gestation
11. Pulsatile secretion of gonadotropins and prolactin during the follicular and luteal phases of the menstrual cycle: Analysis of instantaneous secretion rate and secretory concomitance
12. Differential diagnosis and management of hyperprolactinemia
13. Characterization of a large molecular weight prolactin in women with idiopathic hyperprolactinemia and normal menses
14. Hyperprolactinemia and male infertility
15. Prolactin-secreting tumors and hypogonadism in 22 men
16. The importance of pituitary tumor size in patients with hyperprolactinemia in relation to hormonal variables and extrasellar extension of tumour
17. Prolactinomas
18. Surgical indication after bromocriptine therapy on giant prolactinomas: Effects and limitations of the medical treatment
19. The pharmacokinetics of bromocriptine in man
20. A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: A study of serum prolactin and bromocriptine levels after a cure and chronic administration of bromocriptine
21. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: Results of a prospective multicenter study
22. Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study
23. Dopaminergic inhibition of prolactin synthesis and prolactin messenger RNA accumulation in cultured pituitary cells
24. Vaginal bromocriptine - Clinical and biochemical effects
25. Psychotic reactions during treatment of pituitary tumours with dopamine agonists
26. Pleuropulmonary disease as a side-effect of treatment with bromocriptine
27. Effect of bromocriptine and pergolide on pituitary tumor size and serum prolactin
28. In vivo interaction of CAB with rat brain dopamine receptors labeled with H-N-n propylinorapomorphine
29. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline
30. Cabergoline in the treatment of hyperprolactinemia: A study of 455 patients
31. Continuous administration of bromocriptine in the preventioin of neurological complications in pregnant women with prolactinomas
32. Pregnancy outcome after treatment with the ergot derivative, cabergoline
33. Pregnancy and the hyperprolactinemic woman
34. Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas
35. Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea
36. Dopaminergic factors in human prolactin regulation: Effects of neuroleptics and dopamine
37. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis
38. Cimetidine effect on dopaminergic modulation of prolactin release in healthy women
39. Augmentation of prolactin secretion by estrogen in hypogonadal women
40. Amenorrhea, galactorrhea and primary hypothyroidism with high circulating levels of prolactin
41. Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure
42. Human prolactin and growth hormone release during surgery and other times of stress